Details of Disease

General Information of Disease (ID: DISDW0SR)

• Disease Name: Gastroparesis
• Synonyms: gastroparesis; gastric atonia; gastroparesis syndrome; gastroparalysis; gastroparesis (disease)
• Disease Class: DA41: Gastroduodenal motor/secretory disorder
• Definition: Paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.
• Disease Hierarchy:
  DISGJGHR: Functional gastric disease
  DISDW0SR: Gastroparesis
• ICD Code:
  ICD-11: ICD-11: DA41.00
  ICD-9: ICD-9: 536.3
  Expand ICD-11: 'DA41.00
  Expand ICD-9: 536.3
• Disease Identifiers:
  MONDO ID: MONDO_0006769
  MESH ID: D018589
  UMLS CUI: C0152020
  MedGen ID: 101809
  HPO ID: HP:0002578
  SNOMED CT ID: 196753007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dexpanthenol	DMUTSRW	Approved	Small molecular drug	[1]
Domperidone	DMBDPY0	Approved	Small molecular drug	[2]
Erythromycin	DM4K7GQ	Approved	Small molecular drug	[3]
Naltrexone	DMUL45H	Approved	Small molecular drug	[4]

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RM-131	DMD709J	Phase 3	NA	[5]
TZP-101	DMOE582	Phase 2b	Small molecular drug	[6]
CNSA-001	DMV9FLB	Phase 2	Small molecular drug	[7]
LD-02GIFRO	DMPT8UU	Phase 2	NA	[8]
TD-5108	DM6SANW	Phase 2	Small molecular drug	[9]
GSK-1322888	DMNYGB8	Phase 1	NA	[10]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GSK-326416	DMFJ0ZA	Preclinical	NA	[11]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 8 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GHSR	TTWDC17	Limited	Biomarker	[12]
SCN10A	TT90XZ8	Limited	Genetic Variation	[13]
ABL2	TT1A6HL	moderate	Biomarker	[14]
CHAT	TTKYFSB	moderate	Biomarker	[15]
GPR55	TTNET8J	moderate	Altered Expression	[16]
HCRTR1	TT60Q8D	moderate	Biomarker	[15]
HTR4	TT07C3Y	moderate	Biomarker	[17]
HMOX1	TTI6V2A	Strong	Altered Expression	[18]

This Disease Is Related to 9 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AK6	OT84OHHP	Limited	Genetic Variation	[19]
MLIP	OTMT7AII	Limited	Genetic Variation	[19]
RETNLB	OT9JJQQQ	Disputed	Altered Expression	[18]
FOXF2	OTV20NGX	moderate	Altered Expression	[20]
NPNT	OTFZAO1G	moderate	Biomarker	[21]
RERE	OT3G4GBZ	moderate	Biomarker	[14]
MLN	OTBZ5SE5	Strong	Biomarker	[22]
POLG	OTDUCT04	Strong	Genetic Variation	[23]
SYMPK	OTYAUDXV	Strong	Biomarker	[24]

References

• [1] Riboflavin FDA Label
• [2] Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013 Jan;108(1):18-37; quiz 38.
• [3] Erythromycin FDA Label
• [4] Naltrexone FDA Label
• [5] ClinicalTrials.gov (NCT03426345) Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02. U.S. National Institutes of Health.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3535).
• [7] ClinicalTrials.gov (NCT03712124) A Study of CNSA-001 in Women With Diabetic Gastroparesis. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT01624571) Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO. U.S. National Institutes of Health.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8425).
• [10] ClinicalTrials.gov (NCT01294566) FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers. U.S. National Institutes of Health.
• [11] Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
• [12] Diminished gastric prokinetic response to ghrelin in a rat model of spinal cord injury.Neurogastroenterol Motil. 2018 Apr;30(4):e13258. doi: 10.1111/nmo.13258. Epub 2017 Dec 5.
• [13] Painful small fiber neuropathy with gastroparesis: A new phenotype with a novel mutation in the SCN10A gene.J Clin Neurosci. 2016 Apr;26:84-8. doi: 10.1016/j.jocn.2015.05.071. Epub 2015 Dec 23.
• [14] Wheat Protein Hydrolysate Fortified With l-Arginine Enhances Satiation Induced by the Capsaicinoid Nonivamide in Moderately Overweight Male Subjects.Mol Nutr Food Res. 2019 Dec;63(23):e1900133. doi: 10.1002/mnfr.201900133. Epub 2019 Oct 2.
• [15] Expression of Dopamine Receptors in the Lateral Hypothalamic Nucleus and Their Potential Regulation of Gastric Motility in Rats With Lesions of Bilateral Substantia Nigra.Front Neurosci. 2019 Mar 14;13:195. doi: 10.3389/fnins.2019.00195. eCollection 2019.
• [16] Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans.Neurogastroenterol Motil. 2018 Sep;30(9):e13370. doi: 10.1111/nmo.13370. Epub 2018 May 10.
• [17] Effects of Motilin Receptor Agonists and Ghrelin in Human motilin receptor Transgenic Mice.Int J Mol Sci. 2019 Mar 27;20(7):1521. doi: 10.3390/ijms20071521.
• [18] Change in Populations of Macrophages Promotes Development of Delayed Gastric Emptying in Mice.Gastroenterology. 2018 Jun;154(8):2122-2136.e12. doi: 10.1053/j.gastro.2018.02.027. Epub 2018 Mar 6.
• [19] Diagnosis and treatment of chronic gastroparesis and chronic intestinal pseudo-obstruction.Gastroenterol Clin North Am. 2003 Jun;32(2):619-58. doi: 10.1016/s0889-8553(03)00028-1.
• [20] Gastroparesis is associated with decreased FOXF1 and FOXF2 in humans, and loss of FOXF1 and FOXF2 results in gastroparesis in mice.Neurogastroenterol Motil. 2019 Mar;31(3):e13528. doi: 10.1111/nmo.13528. Epub 2018 Dec 19.
• [21] Initial Experience with Endoscopic Pyloromyotomy, with Description and Video of Technique.J Gastrointest Surg. 2019 Aug;23(8):1706-1710. doi: 10.1007/s11605-019-04237-6. Epub 2019 May 6.
• [22] Elevated Circulating Levels of Motilin are Associated with Diabetes in Individuals after Acute Pancreatitis.Exp Clin Endocrinol Diabetes. 2020 Jan;128(1):43-51. doi: 10.1055/a-0859-7168. Epub 2019 Mar 14.
• [23] Novel mutation in spacer region of POLG associated with ataxia neuropathy spectrum and gastroparesis.Auton Neurosci. 2012 Sep 25;170(1-2):70-2. doi: 10.1016/j.autneu.2012.06.002. Epub 2012 Jul 16.
• [24] Spatial Patterns From High-Resolution Electrogastrography Correlate With Severity of Symptoms in Patients With Functional Dyspepsia and Gastroparesis.Clin Gastroenterol Hepatol. 2019 Dec;17(13):2668-2677. doi: 10.1016/j.cgh.2019.04.039. Epub 2019 Apr 19.